» Articles » PMID: 28946642

E-Learning for Rare Diseases: An Example Using Fabry Disease

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Sep 27
PMID 28946642
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Rare diseases represent a challenge for physicians because patients are rarely seen, and they can manifest with symptoms similar to those of common diseases. In this work, genetic confirmation of diagnosis is derived from DNA sequencing. We present a tutorial for the molecular analysis of a rare disease using Fabry disease as an example.

Methods: An exonic sequence derived from a hypothetical male patient was matched against human reference data using a genome browser. The missense mutation was identified by running BlastX, and information on the affected protein was retrieved from the database UniProt. The pathogenic nature of the mutation was assessed with PolyPhen-2. Disease-specific databases were used to assess whether the missense mutation led to a severe phenotype, and whether pharmacological therapy was an option.

Results: An inexpensive bioinformatics approach is presented to get the reader acquainted with the diagnosis of Fabry disease. The reader is introduced to the field of pharmacological chaperones, a therapeutic approach that can be applied only to certain Fabry genotypes.

Conclusion: The principle underlying the analysis of exome sequencing can be explained in simple terms using web applications and databases which facilitate diagnosis and therapeutic choices.

Citing Articles

Rare disease 101: an online resource teaching on over 7000 rare diseases in one short course.

Dunne T, Jeffries D, McKay L Orphanet J Rare Dis. 2024; 19(1):275.

PMID: 39039494 PMC: 11265069. DOI: 10.1186/s13023-024-03286-8.


Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease.

Monticelli M, Mele B, Allocca M, Liguori L, Lukas J, Monti M Int J Mol Sci. 2023; 24(2).

PMID: 36674610 PMC: 9863837. DOI: 10.3390/ijms24021095.


Bioinformatics tools for marine biotechnology: a practical tutorial with a metagenomic approach.

Liguori L, Monticelli M, Allocca M, Cubellis M, Mele B BMC Bioinformatics. 2020; 21(Suppl 10):348.

PMID: 32838733 PMC: 7447578. DOI: 10.1186/s12859-020-03560-z.

References
1.
Nash R, Kato A, Yu C, Fleet G . Iminosugars as therapeutic agents: recent advances and promising trends. Future Med Chem. 2011; 3(12):1513-21. DOI: 10.4155/fmc.11.117. View

2.
Germain D, Hughes D, Nicholls K, Bichet D, Giugliani R, Wilcox W . Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med. 2016; 375(6):545-55. DOI: 10.1056/NEJMoa1510198. View

3.
Weidemann F, Niemann M, Stork S, Breunig F, Beer M, Sommer C . Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013; 274(4):331-41. PMC: 4282332. DOI: 10.1111/joim.12077. View

4.
Saito S, Ohno K, Sakuraba H . Fabry-database.org: database of the clinical phenotypes, genotypes and mutant α-galactosidase A structures in Fabry disease. J Hum Genet. 2011; 56(6):467-8. DOI: 10.1038/jhg.2011.31. View

5.
Hughes D, Nicholls K, Shankar S, Sunder-Plassmann G, Koeller D, Nedd K . Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2016; 54(4):288-296. PMC: 5502308. DOI: 10.1136/jmedgenet-2016-104178. View